XML 24 R14.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2023

Intangible Assets

Intangible Assets

8. Intangible Assets


				As of September 30, 2023									As of December 31, 2022
		Estimated life (years)		Cost			Accumulated Amortization			Net			Cost			Accumulated Amortization			Net

Capitalized Milestones		11		$	9,000		$	(1,758)		$	7,242		$	9,000		$	(1,117)		$	7,883

As of September 30, 2023, the Company’s finite-lived net intangible assets, which totaled $7,242 resulted from the capitalization of certain milestone payments made to Ipsen Pharma, S.A.S., or Ipsen, in accordance with the terms of the Company’s license agreement with Ipsen, in connection with the Company’s first commercial sale of IMCIVREE in the U.S. in March 2021 and in France in March 2022.

As of September 30, 2023, amortization expense for the next five years and beyond is summarized as follows:


2023		$	214
2024			855
2025			855
2026			855
2027			855
Thereafter			3,608
Total		$	7,242

Amortization expense totaled $214, $641, $114 and $560 for the three and nine months ended September 30, 2023 and 2022, respectively. Amortization expense is included in cost of sales in the condensed consolidated statements of operations and comprehensive loss.